Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | PRLD |
---|---|---|
10:28 ET | 3707 | 3.76 |
10:33 ET | 2400 | 3.78 |
10:35 ET | 600 | 3.79 |
10:37 ET | 400 | 3.79 |
10:39 ET | 300 | 3.79 |
10:51 ET | 1778 | 3.8199 |
11:42 ET | 700 | 3.8 |
12:02 ET | 100 | 3.95 |
01:01 ET | 100 | 3.79 |
02:29 ET | 612 | 3.8503 |
02:36 ET | 895 | 3.8 |
02:42 ET | 200 | 3.76 |
03:03 ET | 100 | 3.76 |
03:41 ET | 600 | 3.77 |
03:45 ET | 100 | 3.76 |
03:52 ET | 300 | 3.76 |
03:59 ET | 1100 | 3.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Prelude Therapeutics Inc | 208.7M | -2.0x | --- |
Zura Bio Ltd | 208.8M | -1.1x | --- |
Boundless Bio Inc | 211.7M | -4.3x | --- |
Compass Therapeutics Inc. | 214.6M | -4.7x | --- |
Acumen Pharmaceuticals Inc | 201.9M | -3.1x | --- |
Ovid Therapeutics Inc | 213.8M | -4.1x | --- |
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $208.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 54.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.55 |
EPS | $-1.88 |
Book Value | $4.32 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.